Artiva Biotherapeutics, Inc.

ARTV

Explore Our Financial Data > Companies > Artiva Biotherapeutics, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	ARTV
CIK	0001817241
SIC	2836
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Biological Products, Except Diagnostic Substances

Contact

Address	5505 MOREHOUSE DRIVE, SAN DIEGO, CA, 92121
Website	www.artivabio.com
Phone	(858) 267-4467
CEO	Fred Aslan
Employees	N/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	$-75.10 million
Net Income	$-75.13 million
Net Income to Common	$-75.13 million
EPS	$31.73

View All

Balance Sheet

Cash	$28.47 million
Assets	$169.39 million
Liabilities	$20.35 million
Common Equity	$149.04 million
Liabilities & Equity	$169.39 million

View All

Cash Flow Statement

Net Income	$-75.13 million
Cash From Operating Activities	$-69.08 million
Cash From Investing Activities	$-100.50 million
Cash From Financing Activities	$164.01 million
Change in Cash	$-5.58 million

View All

Calculations

NOPAT	$-57.11 million
EBITDA	$-83.13 million
Price to Earnings	N/A
Price to Book	$0.44
ROE	-86.18%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic sclerosis Continued execution and enrollment progress with over a dozen patients treated with AlloNK + mAb across over a dozen sites in company-sponsored and investigator-initiated clinical trials in autoimmune diseases Initial safety, translational data, and lead indication selection for AlloNK in aut

Article Link

Will Artiva Biotherapeutics (NASDAQ:ARTV) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Article Link

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. EDT. Members of the Artiva management team will also be available to participat

Article Link

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL Median duration of response for AlloNK + rituximab not yet reached and is at least 19.4 months, in line with approved auto-CAR-T therapies in aggressive B-NHL AlloNK’s activity and well-tolerated safety profile in aggressive B-NHL patients support the potential to deliver deep B-cell depletion in a ref

Article Link

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren’s disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer

Article Link